Emily Parker @911GlobalMeds
06 March, 03:44
The Effectiveness of Brigatinib over Crizotinib for Treating Non-Small Cell Lung Cancer

Brigatinib / Alunbrig is a cancer medication belonging to the class of anaplastic lymphoma kinase inhibitor or ALK. It has been proven to be efficient in treating non-small cell lung cancer or NSCLC that is ALK positive.

The ALK gene occurs in only 3-5 % of the patients of NSCLC. Crizotinib (also a first generation ALK inhibitor) showed a longer progression-free survival when compared to platinum based double agent chemotherapy medication.

Source: https://shorturl.at/bilG6

#BrigatinibSuccess #NSCLC #LungCancerTreatment #BrigatinibVsCrizotinib #MedicalAdvancements #cancerresearch #TargetedTherapy #PrecisionMedicine #lungcancerawareness #fightagainstcancer #TreatmentBreakthroughs #HealthcareInnovation #SurvivorStories #PersonalizedMedicine #clinicaltrials #BetterOutcomes #ImprovingSurvivalRates #InnovativeMedicine #ProgressInOncology #MedicalBreakthroughs #HopeForPatients #NSCLCTreatment

Notice: Undefined index: tg1tga_access in /home/admin/www/anonup.com/themes/default/apps/timeline/post.phtml on line 396
Emily Parker @911GlobalMeds
02 March, 04:57
Gastric Cancer Treatment with Docetaxel

Chemotherapy drugs kills the cancer cells depends upon their ability on how fast they halt the division of cells.
Docetaxel medication's main function is to damage the DNA or RNA cells which copy itself in the division.
With this drug working, cancer cells are not able to divide, thus leading to death of these cells.
Antimicrotubule agents like Docetaxel (Brand Taxotere) inhibits the microtubule structures within cells.
These microtubules plays a major role in replicating and dividing of cells, and docetaxel results in the untimely death of these cells.

Source: https://shorturl.at/gowDT

#GastricCancer #Docetaxel #cancertreatment #Chemotherapy #CancerTherapy
#medicaltreatment #Oncology #cancerresearch #HealthCare #GastricHealth
#GastricCancerAwareness #cancerfight #cancersurvivor #treatmentoptions
#CancerAwareness #cancercare #beatcancer

Notice: Undefined index: tg1tga_access in /home/admin/www/anonup.com/themes/default/apps/timeline/post.phtml on line 396
Emily Parker @911GlobalMeds
27 February, 01:44
Improved Progression-Free-Survival in Renal Cell Cancer with Everolimus Treatment

Renal Cell Cancer or Renal Cell Carcinoma or RCC is the most common form of kidney cancer that is diagnosed in adults. RCC is fast growing and can often spread from the kidney to nearby organs.

The kidneys help in getting rid of waste and regulating fluid balance through tiny tubes known as tubules. RCC forms when the abnormal cancer cells start growing rapidly in the lining of tubules.

Learn More: https://shorturl.at/yDES7

#RenalCellCancer
#Everolimus
#cancertreatment
#ProgressionFreeSurvival
#ImprovedOutcomes
#RenalCancerAwareness
#fightcancer
#cancerresearch
#MedicalBreakthrough
#SurviveAndThrive
#Cancer
#KIDNEY #kidneydisease #kidneyhealth #kidneydiseaseawareness #kidneydiseasewarrior

Notice: Undefined index: tg1tga_access in /home/admin/www/anonup.com/themes/default/apps/timeline/post.phtml on line 396
Emily Parker @911GlobalMeds
26 February, 05:00
Breast cancer treatment by Everolimus Therapy

Everolimus along with exemestane was approved for treating HER2 negative and HR-positive metastatic breast cancer after anastrozole or letrozole treatment had not shown successful. The results of this study showed that progression free survival was 4 months more for everolimus + exemestane treatment. The median PFS for exemestane + placebo group was 2.8 months as compares to everolimus + exemestane's 6.9 months.

Source: https://shorturl.at/fmCJ7

#EverolimusTherapy #BreastCancerTreatment #cancerresearch #MedicalInnovation #HealthcareAdvances #fightagainstcancer #WomenHealth #MedicalBreakthrough #Oncology #treatmentoptions #CancerTherapy

Notice: Undefined index: tg1tga_access in /home/admin/www/anonup.com/themes/default/apps/timeline/post.phtml on line 396
Emily Parker @911GlobalMeds
23 February, 02:52
Survival Improvements in Ovarian Cancer by using Sorafenib

According to a new study, topotecan and Nexavar (generic Sorafenib) when combined, and there after used as a maintenance therapy has significantly improve the survival outcomes in women who are suffering from platinum-resistant ovarian cancer.

Source: https://shorturl.at/eiCDL

#OvarianCancerSurvival
#SorafenibTreatment
#cancerresearch
#SurvivalImprovements
#ovariancancerawareness
#MedicalAdvancements
#TreatmentInnovation
#fightagainstcancer
#HealthcareBreakthroughs
#cancersurvivor

Notice: Undefined index: tg1tga_access in /home/admin/www/anonup.com/themes/default/apps/timeline/post.phtml on line 396

Nothing found!

Sorry, but we could not find anything in our database for your search query {{search_query}}. Please try again by typing other keywords.